ArticleThe Journal of clinical endocrinology and metabolism2026
The need for pharmacotherapy among patients with one or more elevations on glucose tolerance test.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify factors associated with need for pharmacotherapy among patients with glucose intolerance and 1 elevation on 3-hour oral glucose tolerance test (OGTT).
methodsRetrospective cohort study of singleton gestations 24 weeks or greater with at least 1 elevation on OGTT. The primary outcome was need for pharmacotherapy for glycemic control. To evaluate timing of OGTT elevation with need for pharmacotherapy, a logistic regression model controlled for maternal race/ethnicity, body mass index (BMI), gestational age at time of OGTT, age, parity, history of gestational diabetes, and history of large neonate. The need for pharmacotherapy was assessed based on number and extent of testing elevations. A predictive model based on linear discriminant analysis was developed.
resultsOverall, 480 patients had 1 OGTT elevation; of these, 19.2% required pharmacotherapy. Fasting elevations were most associated with development of medication-requiring diabetes. A predictive model for risk of pharmacotherapy in patients with an abnormal OGTT based on BMI and extent of elevation at each OGTT time point increased the identification of patients requiring pharmacotherapy by 15.4%. At least 2 OGTT elevations occurred in 376 patients; these patients were more likely to require pharmacotherapy for glycemic control compared to those with 1 elevation. Patients with increasing BMI values had increased need for pharmacotherapy regardless of the number of abnormal values.
conclusionAmong patients with 1 OGTT elevation, fasting elevation and BMI are predictive of need for anti-glycemic medications. Predictive models may be useful in assessing need for pharmacotherapy for patients with abnormal OGTT, not otherwise meeting criteria for gestational diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.